MeMed

MeMed is a diagnostics company based in Haifa, Israel. It applies machine learning to translate the signaling of the immune system into diagnostic insights, addressing clinical challenges in infectious diseases and inflammatory disorders. Its flagship offering, MeMed BV®, is described as the first FDA-cleared host-immune response assay for distinguishing bacterial from viral infections in 15 minutes, and it runs on MeMed Key®, a compact immunoassay platform. MeMed BV and MeMed Key are described as FDA, CE-IVD and AMAR cleared and available in the US, EU, and Israel.

MeMed is a company based in Haifa, Israel. It states that it applies machine learning to translate the complex signaling of the immune system into simple, actionable diagnostic insights, and that its machine learning-based diagnostics address key clinical and medical challenges in infectious diseases and inflammatory disorders. The company describes starting with the problem of determining whether a patient with a suspected infection has a bacterial or viral infection, which MeMed BV® addresses, and states that it is next tackling the question of whether a patient is likely to have a severe infection through MeMed Severity. MeMed states that it combines molecular immunology, machine learning, engineering and clinical expertise to decode host-response signaling and identify and measure biomarkers linked to specific clinical conditions.

Machine learning-based host-immune response diagnostics for infectious diseases and inflammatory disorders.

• MeMed BV®

  A 15-minute test that differentiates between bacterial and viral infections; described as the first FDA-cleared host-immune response assay for this purpose, and as FDA-cleared and CE-Marked, running on serum or venous whole blood.

• MeMed Key®

  A compact immunoassay platform that enables highly sensitive, quick, multiplexed protein measurements; described as FDA-cleared and as the platform on which MeMed's tests run.

• MeMed Severity

  Designed to provide clinicians with an actionable result that helps assess the likelihood of deterioration in patients with suspected acute infection.

• 2020-09-08

  DiaSorin and MeMed partner to commercialize MeMed BV[5]DiaSorin 与 MeMed 合作商业化 MeMed BVfinanznachrichten.de

  Reported: 2020-09-08

  DiaSorin and MeMed announced a strategic partnership under which DiaSorin obtained rights to commercialize MeMed BV on its LIAISON analyzer family. The companies said the test would be made available on more than 5,000 installed LIAISON XL and XS platforms worldwide.

1. 1Rapid Infection Diagnostics | Bacterial vs Viral Test | MeMedme-med.com
2. 2Our Products | Diagnostic Host Immune Response Solutionsme-med.com
3. 3About Us - Transformative Diagnostic Solutions | MeMedme-med.com
4. 4MeMed (Israel)wikidata.org
5. 5DiaSorin 与 MeMed 合作商业化 MeMed BVfinanznachrichten.de